August 17, 2022 6:59 am
The BBV154 intranasal Covid vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials, the company said.
July 31, 2022 7:09 am
Phase 3 trial for BB’s nasal vaccine was announced as completed in June this year and the company is yet to submit the trial data with the DCGI.
April 08, 2022 3:53 pm
Various countries, including Australia, have already recognised Covaxin for facilitating travel
April 05, 2022 9:26 am
On Saturday, the WHO had suspended the procurement of Covaxin by UN agencies, asking Bharat Biotech for facility upgrade to address the identified GMP deficiencies. The WHO, however, had highlighted that Covaxin is effective and no safety concern exists.
April 04, 2022 8:59 pm
Covaxin has received emergency use approvals from over 25 countries.
April 02, 2022 12:38 am
Covaxin is the second most commonly used Covid-19 vaccine in India and the only one being administered to those between ages 15 and 17 years under the government’s programme.
January 28, 2022 3:39 pm
The approval comes soon after Covaxin and Serum Institute of India's Covishield were cleared for sale in the market.
January 09, 2022 3:40 am
Six months after the second Covaxin dose, a study using the vaccine as a booster dose has detected neutralising, T and B cell responses. This suggests good immune memory responses and long-term protection from severe disease, an official statement from Bharat Biotech said.
January 08, 2022 11:05 am
🔴 Like any vaccine, Covid-19 vaccines can cause side effects, most of which are mild or moderate and go away within a few days.
December 21, 2021 8:21 am
An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.